ZIVO Bioscience, Inc. (ZIVO)
USD 16.02
(-15.68%)
USD 16.02
(-15.68%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -7.26 Million USD | 16.82% |
| 2022 | -8.73 Million USD | 3.54% |
| 2021 | -9.05 Million USD | -5.81% |
| 2020 | -550.05 Thousand USD | -2.43% |
| 2019 | -8.35 Million USD | -27.75% |
| 2018 | -6.13 Million USD | -0.16% |
| 2017 | -6.33 Million USD | -79.06% |
| 2016 | -3.49 Million USD | -13.51% |
| 2015 | -3.05 Million USD | 17.57% |
| 2014 | -5.15 Million USD | -26.31% |
| 2013 | -3.11 Million USD | -53.78% |
| 2012 | -2.08 Million USD | -554.59% |
| 2011 | -1.93 Million USD | 68.61% |
| 2010 | -4.02 Million USD | 74.28% |
| 2009 | -2.61 Million USD | -552.09% |
| 2008 | -1.17 Million USD | 73.85% |
| 2007 | -2.12 Million USD | 37.7% |
| 2006 | -3.2 Million USD | -5723.15% |
| 2005 | -2.73 Million USD | 98.4% |
| 2004 | -3.84 Million USD | -610.44% |
| 2003 | -540.81 Thousand USD | -15667.26% |
| 2002 | -3430.00 USD | -66.91% |
| 2001 | -2055.00 USD | 43.09% |
| 2000 | -3611.00 USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -8.22 Million USD | -545.03% |
| 2024 Q1 | -1.27 Million USD | 32.73% |
| 2023 Q1 | -1.97 Million USD | 25.31% |
| 2023 FY | - USD | 16.82% |
| 2023 Q4 | -1.89 Million USD | -20.62% |
| 2023 Q3 | -1.57 Million USD | 13.79% |
| 2023 Q2 | -1.82 Million USD | 7.43% |
| 2022 Q4 | -2.63 Million USD | -31.88% |
| 2022 FY | - USD | 3.54% |
| 2022 Q2 | -2.06 Million USD | -2.03% |
| 2022 Q3 | -2 Million USD | 3.26% |
| 2022 Q1 | -2.02 Million USD | 35.94% |
| 2021 Q3 | -2.05 Million USD | -17.52% |
| 2021 Q1 | -2.08 Million USD | -18.72% |
| 2021 Q4 | -3.16 Million USD | -53.88% |
| 2021 Q2 | -1.74 Million USD | 16.04% |
| 2021 FY | - USD | -5.81% |
| 2020 Q3 | -3.36 Million USD | -226.68% |
| 2020 Q2 | -1.02 Million USD | 57.2% |
| 2020 FY | - USD | -2.43% |
| 2020 Q1 | -2.4 Million USD | 36.22% |
| 2020 Q4 | -1.75 Million USD | 47.84% |
| 2019 Q4 | -3.77 Million USD | -139.69% |
| 2019 Q1 | -967.85 Thousand USD | 40.62% |
| 2019 Q2 | -2.03 Million USD | -110.55% |
| 2019 FY | - USD | -27.75% |
| 2019 Q3 | -1.57 Million USD | 22.76% |
| 2018 Q1 | -3.25 Million USD | -30.22% |
| 2018 Q3 | -1.5 Million USD | -5.84% |
| 2018 FY | - USD | -0.16% |
| 2018 Q4 | -1.62 Million USD | -8.05% |
| 2018 Q2 | -1.42 Million USD | 56.19% |
| 2017 FY | - USD | -79.06% |
| 2017 Q2 | -875.19 Thousand USD | -0.02% |
| 2017 Q1 | -875.02 Thousand USD | -32.8% |
| 2017 Q4 | -2.49 Million USD | -9.59% |
| 2017 Q3 | -2.27 Million USD | -160.44% |
| 2016 FY | - USD | -13.51% |
| 2016 Q4 | -658.9 Thousand USD | 7.96% |
| 2016 Q3 | -715.86 Thousand USD | 53.71% |
| 2016 Q2 | -1.54 Million USD | -32.59% |
| 2016 Q1 | -1.16 Million USD | -235.74% |
| 2015 Q2 | -1.42 Million USD | -133.38% |
| 2015 FY | - USD | 17.57% |
| 2015 Q4 | -347.36 Thousand USD | 58.18% |
| 2015 Q3 | -830.65 Thousand USD | 41.65% |
| 2015 Q1 | -609.96 Thousand USD | 43.86% |
| 2014 Q2 | -794.46 Thousand USD | -2.84% |
| 2014 Q1 | -772.5 Thousand USD | -123.83% |
| 2014 FY | - USD | -26.31% |
| 2014 Q4 | -1.08 Million USD | 12.57% |
| 2014 Q3 | -1.24 Million USD | -56.42% |
| 2013 Q4 | 3.24 Million USD | 237.6% |
| 2013 Q3 | -2.35 Million USD | -166.97% |
| 2013 Q2 | -882.4 Thousand USD | -34.79% |
| 2013 FY | - USD | -53.78% |
| 2013 Q1 | -654.64 Thousand USD | 32.48% |
| 2012 Q4 | -969.5 Thousand USD | -155.03% |
| 2012 Q2 | -777.78 Thousand USD | -231.98% |
| 2012 Q3 | -380.15 Thousand USD | 51.12% |
| 2012 FY | - USD | -554.59% |
| 2012 Q1 | 589.3 Thousand USD | 109.91% |
| 2011 Q4 | 280.74 Thousand USD | 10267.25% |
| 2011 Q1 | -460.6 Thousand USD | -106.51% |
| 2011 Q2 | -208.04 Thousand USD | 54.83% |
| 2011 Q3 | 2708.00 USD | 101.3% |
| 2011 FY | - USD | 68.61% |
| 2010 Q1 | 3.61 Million USD | 270.03% |
| 2010 Q2 | -11.07 Million USD | -406.83% |
| 2010 Q3 | -520.33 Thousand USD | 95.3% |
| 2010 Q4 | 7.07 Million USD | 1458.87% |
| 2010 FY | - USD | 74.28% |
| 2009 Q2 | -289.17 Thousand USD | 22.01% |
| 2009 Q4 | -2.12 Million USD | -109.71% |
| 2009 Q3 | -1.01 Million USD | -250.12% |
| 2009 FY | - USD | -552.09% |
| 2009 Q1 | -370.8 Thousand USD | -189.25% |
| 2008 Q3 | -231.22 Thousand USD | 43.78% |
| 2008 Q1 | 115.25 Thousand USD | 130.27% |
| 2008 FY | - USD | 73.85% |
| 2008 Q2 | -411.25 Thousand USD | -456.82% |
| 2008 Q4 | 415.46 Thousand USD | 279.68% |
| 2007 Q4 | -380.76 Thousand USD | 44.61% |
| 2007 Q1 | -675.62 Thousand USD | -49.23% |
| 2007 Q2 | -481.78 Thousand USD | 28.69% |
| 2007 Q3 | -687.44 Thousand USD | -42.69% |
| 2007 FY | - USD | 37.7% |
| 2006 FY | - USD | -5723.15% |
| 2006 Q2 | -1.21 Million USD | -76.65% |
| 2006 Q3 | -961.78 Thousand USD | 20.54% |
| 2006 Q4 | -452.73 Thousand USD | 52.93% |
| 2006 Q1 | -685.23 Thousand USD | -11.55% |
| 2005 Q2 | -395.28 Thousand USD | -26.16% |
| 2005 Q4 | -614.31 Thousand USD | -153.57% |
| 2005 Q1 | -313.32 Thousand USD | 41.98% |
| 2005 FY | - USD | 98.4% |
| 2005 Q3 | 1.14 Million USD | 390.12% |
| 2004 Q2 | -414.1 Thousand USD | 74.33% |
| 2004 FY | - USD | -610.44% |
| 2004 Q4 | -539.99 Thousand USD | 0.94% |
| 2004 Q1 | -1.61 Million USD | -199.95% |
| 2004 Q3 | -545.12 Thousand USD | -31.64% |
| 2003 Q2 | -561.00 USD | 70.4% |
| 2003 FY | - USD | -15667.26% |
| 2003 Q4 | -537.8 Thousand USD | -95764.53% |
| 2003 Q1 | -1895.00 USD | -237.79% |
| 2003 Q3 | -561.00 USD | 0.0% |
| 2002 Q2 | -597.00 USD | 63.46% |
| 2002 Q1 | -1634.00 USD | -166.56% |
| 2002 FY | - USD | -66.91% |
| 2002 Q4 | -561.00 USD | 12.07% |
| 2002 Q3 | -638.00 USD | -6.87% |
| 2001 Q2 | -620.00 USD | -196.65% |
| 2001 Q4 | -613.00 USD | 0.0% |
| 2001 FY | - USD | 43.09% |
| 2001 Q3 | -613.00 USD | 1.13% |
| 2001 Q1 | -209.00 USD | 90.62% |
| 2000 Q4 | -2228.00 USD | -257.62% |
| 2000 Q2 | -460.00 USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q3 | -628.00 USD | -35.43% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q3 | -15.23 Thousand USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| America Great Health | -447.29 Thousand USD | -1523.774% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | 75.385% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 93.632% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | 53.918% |
| Better Therapeutics, Inc. | -38.26 Million USD | 81.018% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 81.019% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | 59.394% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | 78.469% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | 78.237% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 93.17% |
| Evolutionary Genomics, Inc. | -913.47 Thousand USD | -695.099% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | 77.64% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 84.445% |
| Innovation1 Biotech Inc. | -5.68 Million USD | -27.786% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | 55.445% |
| Molecular Templates, Inc. | 1.43 Million USD | 607.903% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | 47.654% |
| NexImmune, Inc. | -28.16 Million USD | 74.215% |
| Orgenesis Inc. | -60.71 Million USD | 88.038% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 85.84% |
| Point of Care Nano-Technology, Inc. | -73.41 Thousand USD | -9792.955% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 55.015% |
| Scopus BioPharma Inc. | -11.71 Million USD | 37.993% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 98.655% |
| Statera Biopharma, Inc. | 38.93 Million USD | 118.654% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | -5.506% |
| Trevena, Inc. | -35.28 Million USD | 79.418% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -12857.863% |
| Vaccinex, Inc. | -19.74 Million USD | 63.222% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -593.712% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 84.501% |